日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

PARP7 负向调节癌细胞中的 I 型干扰素反应,其抑制可触发抗肿瘤免疫

Joseph M Gozgit, Melissa M Vasbinder, Ryan P Abo, Kaiko Kunii, Kristy G Kuplast-Barr, Bin Gui, Alvin Z Lu, Jennifer R Molina, Elena Minissale, Kerren K Swinger, Tim J Wigle, Danielle J Blackwell, Christina R Majer, Yue Ren, Mario Niepel, Zacharenia A Varsamis, Sunaina P Nayak, Ellen Bamberg, Jan-Run

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib

在肺癌和结直肠癌中观察到的 RET 融合对普纳替尼敏感

Joseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott Wardwell, Frank Wang, Jie Cai, Henry Li, Henrik Edgren, Victor M Rivera, Justin Pritchard

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors

针对实体肿瘤激酶融合检测的靶向 RNA 测序分析的验证

Julie W Reeser, Dorrelyn Martin, Jharna Miya, Esko A Kautto, Ezra Lyon, Eliot Zhu, Michele R Wing, Amy Smith, Matthew Reeder, Eric Samorodnitsky, Hannah Parks, Karan R Naik, Joseph Gozgit, Nicholas Nowacki, Kurtis D Davies, Marileila Varella-Garcia, Lianbo Yu, Aharon G Freud, Joshua Coleman, Dara L

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

在所有肺癌组织学类型中,FGFR1 mRNA 和蛋白质表达,而不是基因拷贝数,可以预测 FGFR TKI 的敏感性

Wynes Murry W, Hinz Trista K, Gao Dexiang, Martini Michael, Marek Lindsay A, Ware Kathryn E, Edwards Michael G, Böhm Diana, Perner Sven, Helfrich Barbara A, Dziadziuszko Rafal, Jassem Jacek, Wojtylak Szymon, Sejda Aleksandra, Gozgit Joseph M, Bunn Paul A Jr, Camidge D Ross, Tan Aik-Choon, Hirsch Fred R, Heasley Lynn E

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

帕奈替尼可抑制多克隆耐药性 KIT 癌蛋白,并对接受过大量治疗的胃肠道间质瘤 (GIST) 患者显示出治疗潜力

Andrew P Garner #, Joseph M Gozgit #, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C Heinrich, Jonathan A Fletcher, Sebastian Bauer, Victor

Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

非扩增型 FGFR1 是恶性胸膜间皮瘤的生长驱动因素

Marek Lindsay A, Hinz Trista K, von Mässenhausen Anne, Olszewski Kyle A, Kleczko Emily K, Boehm Diana, Weiser-Evans Mary C, Nemenoff Raphael A, Hoffmann Hans, Warth Arne, Gozgit Joseph M, Perner Sven, Heasley Lynn E

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

Ponatinib治疗难治性急性髓系白血病患者:一项1期研究的结果

Shah, Neil P; Talpaz, Moshe; Deininger, Michael W N; Mauro, Michael J; Flinn, Ian W; Bixby, Dale; Lustgarten, Stephanie; Gozgit, Joseph M; Clackson, Tim; Turner, Christopher D; Haluska, Frank G; Kantarjian, Hagop; Cortes, Jorge E

Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers

Paralemmin-1在雌激素受体阳性乳腺癌中过度表达

Turk, Casey M; Fagan-Solis, Katerina D; Williams, Kristin E; Gozgit, Joseph M; Smith-Schneider, Sallie; Marconi, Sharon A; Otis, Christopher N; Crisi, Giovanna M; Anderton, Douglas L; Kilimann, Manfred W; Arcaro, Kathleen F

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

普纳替尼 (AP24534) 在 FLT3 驱动的急性髓系白血病和其他血液系统恶性肿瘤模型中具有强效活性

Joseph M Gozgit, Matthew J Wong, Scott Wardwell, Jeffrey W Tyner, Marc M Loriaux, Qurish K Mohemmad, Narayana I Narasimhan, William C Shakespeare, Frank Wang, Brian J Druker, Tim Clackson, Victor M Rivera

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

JAK2 抑制剂 AZD1480 可有效阻断实体肿瘤中的 Stat3 信号传导和癌变

Michael Hedvat, Dennis Huszar, Andreas Herrmann, Joseph M Gozgit, Anne Schroeder, Adam Sheehy, Ralf Buettner, David Proia, Claudia M Kowolik, Hong Xin, Brian Armstrong, Geraldine Bebernitz, Shaobu Weng, Lin Wang, Minwei Ye, Kristen McEachern, Huawei Chen, Deborah Morosini, Kirsten Bell, Marat Alimzh